The coronavirus, which causes the respiratory sickness COVID-19, has unfold throughout the globe with unseen velocity and ferocity. The world has beenin an try to curb the unfold and , together with the Tokyo Olympics, have been postponed or canceled. and mitigate intensive transmission locally, whereas scientists and researchers flip their consideration to the inflicting the illness: SARS-CoV-2.
Since coronavirus was first found because the causative agent of COVID-19, scientists have been racing to get a greater understanding of the virus’ genetic make-up and unravel easy methods to successfully deal with infections. There is no treatment and medical specialists can solely deal with the signs of the illness. Many various therapy choices have been proposed and a few older medicine appear to be related to optimistic outcomes — however far more work is required. Nonetheless, the long-term technique to fight COVID-19, which has unfold to each continent on Earth apart from Antarctica, is to develop a vaccine.
Creating new vaccines takes time, they usually have to be rigorously examined and confirmed secure by way of medical trials earlier than they are often routinely utilized in people. Dr. Anthony Fauci, director of the Nationwide Institute of Allergy and Infectious Ailments within the US, has steadily said vaccine is at the least a 12 months to 18 months away. Specialists agree there is a methods to go but.
Vaccines are extremely necessary within the battle towards illness. We have been capable of preserve a handful of viral illnesses at bay for many years due to vaccine improvement. Even so, there exists confusion and unease about their usefulness. This information explains what vaccines are, why they’re so necessary and the way scientists will use them within the battle towards the coronavirus. It additionally discusses the present therapy choices getting used and those who present promise in hospitals.
As extra candidates seem and are examined, we’ll add them to this listing, so bookmark this web page and test again for the most recent updates.
You’ll be able to soar to any section by clicking the hyperlinks under:
What’s a vaccine?
A vaccine is a sort of therapy geared toward stimulating the physique’sto fight against infectious pathogens, like bacteria and viruses. They are, according to the World Health Organization, “one of the most effective ways to prevent diseases.”
The human body is particularly resilient to disease, having evolved a natural defense system against nasty disease-causing microorganisms like bacteria and viruses. The defense system — our immune system — is composed of different types of white blood cells that can detect and destroy foreign invaders. Some gobble up bacteria, some produce antibodies which can tell the body what to destroy and take out the germs, and other cells memorize what the invaders look like, so the body can respond quickly if they invade again.
Vaccines are a really clever fake-out. They make the body think it’s infected so it stimulates this immune response. For instance, the measles vaccine tricks the body into thinking it has measles. When you are vaccinated for measles, your body generates a record of the measles virus. If you come into contact with it in the future, the body’s immune system is primed and ready to beat it back before you can get sick.
The very first vaccine was developed by a scientist named Edward Jenner in the late 18th century. In a famous experiment, Jenner scraped pus from a milkmaid with cowpox — a type of virus that causes disease mostly in cows and is very similar to the smallpox virus — and introduced the pus into a young boy. The young boy became a little ill and had a mild case of cowpox. Later, Jenner inoculated the boy with smallpox, but he didn’t get sick. Jenner’s first injection of cowpox pus trained the boy’s body to recognize the cowpox virus and, because it’s so similar to smallpox, the young man was able to fight it off and not get sick.
Vaccines have come an incredibly long way since 1796. Scientists certainly don’t inject pus from patients into other patients, and vaccines must abide by strict safety regulations, multiple rounds of clinical testing and strong governmental guidelines before they can be adopted for widespread use.
What’s in a vaccine?
Vaccines contain a handful of different ingredients depending on their type and how they aim to generate an immune response. However, there’s some commonality between them all.
The most important ingredient is the antigen. This is the part of the vaccine the body can recognize as foreign. Depending on the type of vaccine, an antigen could be molecules from viruses like a strand of DNA or a protein. It could instead be weakened versions of live viruses. For instance, the measles vaccine contains a weakened version of the measles virus. When a patient receives the measles vaccine, their immune system recognizes a protein present on the measles virus and learns to fight it off.
A second important ingredient is the adjuvant. An adjuvant works to amplify the immune response to an antigen. Whether a vaccine contains an adjuvant depends on the type of vaccine it is.
Some vaccines used to be stored in vials that could be used multiple times and, as such, contained preservatives that ensured they would be able to sit on a shelf without growing other nasty bacteria inside them. One such preservative is thimerosal, which has garnered a lot of attention because it contains trace amounts of easily cleared ethylmercury. Its inclusion in vaccines hasn’t been shown to cause harm, according to the CDC. In places like Australia, single-use vials are now common, and thus preservatives such as thimerosal are no longer necessary in most vaccines.
In developing a vaccine for SARS-CoV-2, scientists need to find a viable antigen that will stimulate the body’s immune system into defending against infection.
Making a COVID-19 vaccine
The pathogen at the center of the outbreak, SARS-CoV-2, belongs to the family of viruses known as coronaviruses. This family is so named because, under a microscope, they appear with crownlike projections on their surface.
In developing a vaccine that targets SARS-CoV-2, scientists are looking at these projections intensely. The projections enable the virus to enter human cells where it can replicate and make copies of itself. They’re known as “spike proteins” or “S” proteins., and research suggests they could be a viable antigen in any coronavirus vaccine.
That’s because the S protein is prevalent in coronaviruses we’ve battled in the past — including the one that caused the SARS outbreak in China in 2002-03. This has given researchers a head start on building vaccines against part of the S protein and, using animal models, they’ve demonstrated they can generate an immune response.
There are many companies across the world working on a SARS-CoV-2 vaccine, developing different ways to stimulate the immune system. Some of the most talked about approaches are those using a relatively novel type of vaccine known as a “nucleic acid vaccine.” These vaccines are essentially programmable, containing a small piece of genetic code to act as the antigen.
Biotech companies like Moderna have been able to generate new vaccine designs against SARS-CoV-2 rapidly by taking a piece of the genetic code for the S protein and fusing it with fatty nanoparticles that can be injected into the body. Imperial College London is designing a similar vaccine using coronavirus RNA — its genetic code. Pennsylvania biotech company Inovio is generating strands of DNA it hopes will stimulate an immune response. Although these kinds of vaccines can be created quickly, none have been brought to market yet.
Johnson & Johnson and French pharmaceutical giant Sanofi are both working with the US Biomedical Advanced Research and Development Authority to develop vaccines of their own. Sanofi’s plan is to mix coronavirus DNA with genetic material from a harmless virus, whereas Johnson & Johnson will attempt to deactivate SARS-CoV-2, essentially switching off its ability to cause illness while ensuring it still stimulates the immune system.
On March 30, Johnson & Johnson said human tests of its experimental vaccine will begin by September. “we have a candidate that has a high degree of probability of being successful against the covid-19 virus,” said Alex Gorsky, CEO of Johnson & Johnson, during an interview with NBC News’ Today. “”Literally within the next few days and weeks, we’re going to start ramping up production of these vaccines.”
DIOSynVax, a vaccine development company working out of the University of Cambridge, is trying to eschew the traditional pathways to vaccine creation with a new platform. The company’s approach uses computer modelling of the virus’s structure to determine weak spots in the SARS-CoV-2 DNA — places it can target to drive an immune reaction without causing any harm to the patient. “What we end up with is a mimic, a mirror image of part of the virus, but minus its bad parts,” said Jonathan Heeney, CEO and founder of DIOSynVax, in a statement. “What remains is just the magic bullet, essentially, to trigger the right type of immune response.”
Some research organizations, such as Boston Children’s Hospital, are examining different kinds of adjuvants that will help amplify the immune response. This approach, according to the Harvard Gazette, will be targeted more toward the elderly, who don’t respond as effectively when vaccinated. It’s hoped that by studying adjuvants to boost a vaccine, the elderly can be vaccinated with a mix of ingredients that would supercharge their immunity.
When will a vaccine be available?
Fauci, of the infectious diseases institute, posits that a vaccine is roughly a year and a half away, even though we’re likely to see human trials start within the next month or two. This, according to a 60 Minutes interview with Fauci in March, is a fast turnaround.
“The good news is we did it more quickly than we’ve ever done it,” Fauci told 60 Minutes. (Note: 60 Minutes and CNET share a common parent company, ViacomCBS.) “The sobering news is that it’s not ready for prime time, for what we’re going through now.”
Why does vaccine production take so long? There are many steps involved and a lot of regulatory hurdles to jump through.
“For any medicine to be sold it needs to go through the standard process of clinical trials including phase 1 [to] 3 trials,” said Bruce Thompson, dean of health at Swinburne University in Australia. “We need to ensure that the medicine is safe, will not do harm, and know how effective it is.”
Scientists can’t assume their vaccine design will just work — they have to test, test and test again. They have to recruit thousands of people to ensure the safety of a vaccine and how useful it will be. The process can be broken down into six phases:
- Vaccine design: Scientists study a pathogen and decide on how they will get the immune system to recognize it.
- Animal studies: A new vaccine is tested in animal models for disease to show that it works and has no extreme adverse effects.
- Clinical trials (phase I): These represent the first tests in human beings and test the safety, dose and side effects of a vaccine. These trials only enroll a small cohort of patients.
- Clinical trials (phase II): This is a deeper analysis of how the drug or vaccine actually works biologically. It involves a larger cohort of patients and assesses the physiological responses and interactions with the treatment. For instance, a coronavirus trial may assess if a vaccine stimulates the immune system in a certain way.
- Clinical trials (phase III): The final phase of trials sees an even greater amount of people tested over a long period of time.
- Regulatory approval: The final hurdle sees regulatory agencies, like the US Food and Drug Administration, the European Medicines Agency and Australia’s Therapeutic Goods Administration, take a look at the available evidence from experiments and trials and conclude whether a vaccine should be given the all-clear as a treatment option.
Traditionally, then, it could take a decade or more for a new vaccine to go from design to approval. In addition, once the regulatory processes have concluded a vaccine is safe, the drug companies have to send production into overdrive, so they can manufacture enough of the vaccine to increase immunity in the wider population.
With SARS-CoV-2, the process is being expedited in some instances. As STATnews reports, the vaccine in development by Moderna has moved from design straight into Phase I clinical trials of its mRNA vaccine, skipping tests in animal models. Those tests will take place at Seattle’s Kaiser Permanente Washington Health Institute, and patients are now being enrolled.
First US COVID-19 vaccine trials in humans
In the US, Moderna’s Phase I clinical trials began on March 16 in collaboration with NIAID, the US National Institutes of Health and KPWHRI. It is the first testing in humans of the mRNA vaccine and will look to enroll a total of 45 healthy adult volunteers aged between 18 and 55 years.
“This Phase 1 study, launched in record speed, is an important first step toward achieving that goal,” Fauci said in a statement.
Moderna’s approach, explained in the Vaccines section above, is particularly unique in its speed. Because the biotech company was already researching ways to tackle the coronavirus which causes Middle East respiratory syndrome, they were able to adapt their methodology and vaccine design for SARS-CoV-2. The experimental vaccine, dubbed mRNA-1273, contains genetic material from the spike protein present in SARS-CoV-2 embedded within a lipid nanoparticle.
Manufacturing costs were supported by the Coalition for the Epidemic Preparedness Innovations.
The trial will see patients receive two injections of the mRNA-1273 28 days apart. The 45 patients will be divided into three groups of 15 and given differing doses: Either 25 micrograms, 100 micrograms or 250 micrograms. Safety reviews will be performed after the first four patients receive the lowest and middle doses and again before all patients receive their shots. Another safety review of data will be performed before the 15 patients set to receive the highest dose are a injected.
Even if the vaccine is proven to be safe and shows promise in protecting against COVID-19, it could still be a year away — at least.
The US NIH has added a second site to the clinical trial of Moderna’s vaccine as of March 27. Emory University in Atlanta now be enrolling healthy adult volunteers aged between 18 and 55 into a Phase I trial. This will be an extension of the trial carried out in Seattle — and the ultimate goal is to enroll 45 participants across the two states.
You can visit NIAID’s website for all the information on the trial.
Australia’s ferret fix
Australia’s Commonwealth Scientific and Industrial Research Organisation (CSIRO) has begun testing two promising vaccine candidates in preclinical trials — those performed in animals. Partnering with the Coalition for Epidemic Preparedness Innovations, CSIRO will test candidates being produced by the University of Oxford and by US pharmaceutical company Inovio in ferrets.
“The ferret, we know, does have the specific receptor on cells in its lungs for the virus to be able to infect it,” says Trevor Drew, director of the Australian Animal Health Laboratory where the preclinical trials are taking place. Drew is referring to ACE2, which is a protein the SARS-CoV-2 virus uses to get inside human cells. Drew says the similarity between ferret and human ACE2 receptors making the slinky mustelid a great animal model for testing the immune response.
The vaccine candidates will be injected into ferrets either through the nose or directly into the muscle. CSIRO will examine the level of immunity provided to the lungs, where the virus replicates, by comparing vaccinated animals with unvaccinated controls.
The vaccine candidate pioneered by Oxford University uses another type of virus — an adenovirus — to deliver a small piece of the SARS-CoV-2 genetic sequence into the body. This type of vaccine has proven safe and effective in the past, but there is still a lot of work to do to ensure it is safe and effective in COVID-19 patients.
The second candidate is a DNA vaccine developed by Inovio, a Pennsylvania-based pharmaceutical company. Using proprietary technology Inovio’s vaccine candidate, INO-4800, is injected into the body to stimulate a particular type of immune cell — a T cell — and antibodies against the coronavirus.
Drew says the vaccines will be delivered to ferrets in a single dose before they are challenged with the SARS-CoV-2 virus. He expects to see the first results from the preclinical trials in June.
How do you treat COVID-19?
The best way to prevent illness is avoiding exposure. Those tips are below.
First: Antibiotics, medicine designed to fight bacteria, won’t work on SARS-CoV-2, a virus. If you’re infected, you will be asked to self-isolate, to prevent further spread of the disease, for 14 days. If symptoms escalate and you experience a shortness of breath, high fever and lethargy, you should seek medical care.
Treating cases of COVID-19 in the hospital is based on managing patient symptoms in the most appropriate way. For patients with severe disease adversely affecting the lungs, doctors place a tube into the airway so that they can be connected to ventilators — machines which help control breathing.
There are no specific treatments for COVID-19 as yet, though a number are in the works, including experimental antivirals, which can attack the virus, and existing drugs targeted at other viruses like HIV which have shown some promise in treating COVID-19.
Remdesivir, an experimental antiviral made by biotech firm Gilead Sciences, has garnered a large part of the limelight. The drug has been used in the US, China and Italy, but only on a “compassionate basis” — essentially, this drug hasn’t received approval but can be used outside of a clinical trial on critically ill patients. Remdesivir isn’t specifically designed to destroy SARS-CoV-2. Instead, it works by knocking out a specific piece of machinery in the virus, known as “RNA polymerase,” which many viruses use to replicate. It has been shown in the past to be effective in human cells and mouse models.
Its effectiveness is still being debated, and much more rigorous study will be needed before this becomes a general treatment for SARS-CoV-2, if it does at all.
Gilead, the manufacturer was granted “orphan status” for remdesivir on March 23, which is usually reserved for development of drugs to diagnose or treat “rare diseases or conditions” that affect less than 200,000 people. The classification bestows a number of incentives on Gilead, including tax breaks and expensive fee waivers and is designed to hasten the development process. It also prevents other generic competitors from selling the drug. However, on March 25, Gilead asked the status to be rescinded after facing significant backlash from the public and presidential candidate, Bernie Sanders.
Encouraging clinical trials in Wuhan and Shenzhen involving over 300 patients of the Japanese influenza drug favipiravir were reported by Chinese scientists in the Guardian on March 18. The drug appeared to shorten the course of the disease, with patients who were given the treatment clearing the virus after just four days, while those who did not took around 11 days.
The drug is manufactured by Fujifilm Toyama Chemical, but the company has declined to comment on the claims. Favipiravir, also known as Avigan, is an antiviral and is designed to target RNA viruses which include coronaviruses and influenza viruses. The drug is thought to disrupt a pathway which helps these viruses to replicate inside cells. According to the Guardian, a source within the Japanese health ministry suggests the drug is not effective in patients showing severe symptoms.
Other treatment options
An HIV medicine, Kaletra/Aluvia, has been used in China to treat COVID-19. According to a release by AbbVie, an Illinois-based pharmaceutical company, the treatment was provided as an experimental option for Chinese patients during “the early days” of fighting the virus. The company suggests it is collaborating with global health authorities including the Centers for Disease Control and Prevention and the World Health Organization.
On March 18, a randomized, controlled trial assessed the effectiveness of the HIV medicine. The results, published in the New England Journal of Medicine, show that adults with severe COVID-19 infections do not seem to benefit from the drug treatment and there was no clinical improvement versus standard care. The authors note additional studies should be undertaken because the treatment may reduce serious complications — such as acute kidney injury or secondary infections — if given at a certain stage of illness.
Trouble with chloroquine and hydroxychloroquine
A drug that has been used to treat malaria for about 70 years, chloroquine has been floated as a potential treatment candidate. It appears to be able to block viruses from binding to human cells and getting inside them to replicate. It also may stimulate the immune system. A letter to the editor in journal Nature on Feb. 4 showed chloroquine was effective in combating SARS-CoV-2. A Chinese study originating from Guangdong reports chloroquine improved patient outcomes and “might improve the success rate of treatment” and “shorten hospital stay.”
Tesla and SpaceX CEO Elon Musk and US President Donald Trump have each touted chloroquine as a possible therapy candidate. Chloroquine phosphate is extensively accessible, but it surely is not with out its unintended effects, and well being officers are warning towards self-medicating. It may give you complications, diarrhea, rashes, itching and muscle issues. It is also used as an additive in fish tank cleaner. In uncommon circumstances, it appears to vastly have an effect on the center muscle and may end up in abnormalities or coronary heart failure. Well being officers in Nigeria have reported circumstances of chloroquine poisoning and on March 23, a person in his 60s and his spouse grew to become critically unwell after self-medicating with chloroquine phosphate, derived from fish tank cleaner. The person later died, and his spouse was positioned into vital care.
A current correspondence within the journal Nature, on March 18, suggests “hydroxychloroquine” — a much less poisonous by-product of the drug — could also be efficient at inhibiting SARS-CoV-2 an infection. That by-product is extensively accessible to deal with illnesses like rheumatoid arthritis and Chinese language researchers have at the least seven medical trials in progress utilizing hydroxychloroquine to deal with an infection.
Combining hydroxychloroquine with the antibiotic azithromycin has additionally been reported to have optimistic affected person outcomes however many specialists query its legitimacy.
Docs in Marseille, France, undertook a low-powered examine with a small quantity of sufferers (36) and steered the mixture of hydroxychloroquine and azithromycin could also be efficient in decreasing how a lot virus was present in a selected a part of the physique. The examine is being extensively cited and even Trump suggested it could be a “game changer”. Nonetheless, many scientists have questioned whether or not or not the examine design and strategies are as much as scratch.
“The outcomes are disputed and the medical trials inconclusive,” says Gaeten Burgio, a medical researcher at Australian Nationwide College. “Thus far, there are not any clear indications that chloroquine or hydroxychloroquine are a therapy choice. Extra medical trials will inform us whether or not hydroxychloroquine or chloroquine are viable choices for COVID-19 therapies.”
Burgio advises towards stockpiling hydroxychloroquine as a result of the drug is vital for treating sufferers with the autoimmune situation Lupus. Elisabeth Bik, a microbiologist and science advisor who runs the weblog Science Integrity Digest, examined the examine intimately and located conflicts of curiosity, an expedited peer-review course of and a handful of inconsistencies within the reporting. The Worldwide Society for Antimicrobial Chemotherapy, which publishes the journal the Marseille examine was printed in, issued an announcement on April four saying ” the article doesn’t meet the Society’s anticipated normal.”
The Meals and Drug Administration commissioner, Stephen Hahn, mentioned the investigations into chloroquine throughout a White Home briefing on March 19. “That is a drug that the president has directed us to take a better take a look at as as to whether an expanded use strategy to that may very well be achieved to truly see if that advantages sufferers,” Hahn stated. Trump introduced the FDA accepted chloroquine for use on a “compassionate use” foundation on March 19.
Hydroxychloroquine has additionally acquired an emergency use authorization by the FDA as of April three, nevertheless there nonetheless stays numerous questions on optimum doses and coverings in relation to COVID-19.
Convalescent plasma remedy
On March 24, the US FDA introduced it could enable entry to “convalescent plasma” for sufferers with severe or instantly life-threatening COVID-19 infections. This type of remedy sees a fraction of the blood from recovered COVID-19 sufferers infused into sick sufferers’ our bodies.
As we have defined above, the immune system is the physique’s defence power. When a virus invades, it sends out a military of cells, together with white blood cells, to battle it off. These cells launch antibodies, which linger within the liquid portion of blood, referred to as “plasma.” If a affected person survives COVID-19, they’re prone to have constructed up an enormous inventory of antibodies of their plasma. The thought is to take a portion of their inventory and infuse it into severely unwell sufferers, hoping the antibodies will stimulate the sufferers’ personal immune system to seek out and start destroying the virus.
This is not the primary time such a remedy can be used; earlier outbreaks of SARS, MERS and the H1N1 influenza pandemic all noticed using convalescent plasma to deal with sufferers. In reality, using convalescent plasma stretches again to the 1918 influenza pandemic.
A report by Chinese language scientists printed in journal The Lancet Infectious Ailments in February steered the therapy choice may very well be viable in battling SARS-CoV-2 and anecdotal proof from China has demonstrated some success, with 91 of 245 sufferers in a trial displaying enchancment, in line with Xinhua.
Within the US, New York Gov. Andrew Cuomo has introduced New York docs will start to check convalescent plasma remedy in a trial beginning in late March.
How one can shield your self from coronavirus now?
It is not a good suggestion to depend on a vaccine to cease the unfold of coronavirus as a result of that is many months away. One of the best ways to cease the unfold, proper now, is to proceed working towards good private hygiene and to restrict interactions with others. “The most effective factor to do is the easy issues like hand washing and hand sanitizing,” Thompson stated.
This outbreak is unprecedented, and altering behaviors is completely vital to stopping the unfold.
There are an enormous variety of assets accessible from the WHO on defending your self towards an infection. It is clear the virus can unfold from individual to individual, and transmission in communities has occurred the world over. Safety boils down to some key issues:
- Washing your fingers: For 20 seconds and no much less! You may get some .
- Sustaining social distancing: Attempt to preserve at the least three ft (1m) away from anybody coughing or sneezing.
- Do not contact your face, eyes or mouth: An extremely troublesome process, however that is how the virus initially will get into the physique.
- Respiratory hygiene measures: Cough and sneeze into your elbow.
- In case you’ve visited a location the place COVID-19 is spreading, then self-isolate for 14 days.
For far more data,
Initially printed in March and consistently up to date as new data turns into accessible.